Member Info for Moneymunch

Great work as usual Pickedpeck, undoubted transformational UPside potential and prospects. In the meantime , every chance we've finally kicked on from sub 2p, given the near term game changing potential and increased buying volume in anticipation, and so 3p plus next stop. Looks like the granting of the Key Patent could land anytime now, which would be company defining, adding exponential value and providing huge leverage in any due diligence from any prospective Major partner who wants to make an early move , especially one of the Animal Healthcare companies , with further updates from the Dog study expected soon. All bodes well and we're now fast approaching a very exciting period with Genflow all set for a Major re-rate or two or three as more good news is delivered. Gl :-)

Hopefully this time, sub 2p has finally been assigned to history...fingers crossed!!! ;-)

Eric stated in his recent iterview, the approval and granting of the Sirt6 key patent in collaboration with University of Rochester, University of Columbia and Albert Einstein College, whereby Genflow has exclusive worldwide rights, "is extremely close", and the following activity has emerged on the EPO Global Dossier, the first since 22nd August 2024, and so every chance news could be imminent, and if granted, would be highly significant and company defining and no doubt add exponential value. Gla holders...Excitement building!!! :-)

08.04.2026 Communication - Re: Power of Attorney (PTOL-308)

02.04.2026 Power of Attorney

02.04.2026 Applicant Response to Pre-Exam Formalities Notice

02.04.2026 Electronic Filing System Acknowledgment Receipt

European Patent Register htTps://share.google/y21pt5bSXrbW8DxzC

...........

Administrative Necessity: A POA is often required when a patent attorney or agent needs to legally act on behalf of the applicant before the IPO or USPTO, especially during contentious amendments or when finalize ownership.

Timing: A POA may be requested at any time, but it is frequently requested when an attorney takes over a file or when the application is being prepared for final issuance (i.e., in order for grant).

Hi Pickedpeck, more compelling research from Genflow from 2024, to back up your opinion on Sirt6 and GLP-1's for obesity. Gl :-)

"these finding could highlight the importance of targeting SIRT6 pharmacology with compounds differentially targeting its multiple enzymatic activities to regulate the co-morbidities associated with obesity."

Published: 20 July 2024

Epigenetic and transcriptional control of adipocyte function by centenarian-associated SIRT6 N308K/A313S mutant

................

Conclusions and future directions

In sum, our results reveal a comprehensive and specific epigenetic and transcriptomic profile in mature adipocytes upon overexpression of a SIRT6 mutant (N308K/A313S), which has a higher prevalence in healthy Ashkenazi centenarians. While the adipogenic process was seemingly unaffected, SIRT6 N308K/A313S overexpression in mature adipocytes led to an ameliorated glucose sensitivity and a deregulation of sympathetic innervation signaling. Our study presents with limitations. The in vitro deacetylase activity (acetyl group) of SIRT6 was shown to be hundreds-fold less potent than its long-chain defatty-acylase activity (malonyl, succinyl, butyryl, myristoyl and palmitoyl groups) on lysine residues [72]. These previously underappreciated histone PTMs are increasingly recognized molecular links between metabolism and epigenetic regulation of gene expression [73]; the role of centSIRT6 enzymatic activity on long-chain fatty acyl lysines remains to be analyzed. A further challenge is understanding how the increased mono-ADP ribosyl-transferase, as in SIRT6 N308K/A313S overexpression in mature adipocytes, may reflect in ameliorated glucose metabolism in the context of obesity [74,75,76]. A major limitation of our findings is that they are entirely based on an established in vitro model. If confirmed in vivo, for example through the generation of “humanized” mice models carrying N308K/A313S, these finding could highlight the importance of targeting SIRT6 pharmacology with compounds differentially targeting its multiple enzymatic activities to regulate the co-morbidities associated with obesity.

This work was supported by GenFlow Bioscience, by the European Commission Horizon 2020 Framework Program (Project 856871—TRANSTEM, to MV) and by grants from the US national Institute of Health, Impetus Grants and Michael Antonov Foundation (to VG).

hTtps://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-024-01710-1

Causes of sarcopenia and frailty in people taking GLP1RAs | Nature Reviews Endocrinology https://share.google/tv92ITwPy0ABv0Isb

" potentially integrating it with existing therapies"

Major Pharma paying billions of dollars for Mash/Liver programs, will no doubt be very interested. Gla ;-)

Published in Pubmed Central 3rd March 2026 by Eric & Co....Gla holders:-)

Transcriptional Control of Hepatocellular Carcinoma Cells Aggressiveness by AAV2/8-Mediated Delivery of Human Centenarian-Associated SIRT6 N308K/A313S

Maanya Vittal 1, Niccolo Liorni 2, Ahmed Kazaili 3, Eric Leire 4,5, Riaz Akhtar 3, Tommaso Mazza 2, Manlio Vinciguerra

Simple Summary

Hepatocellular carcinoma, a major type of liver cancer and a leading cause of cancer deaths worldwide, is often linked to poor outcomes due to aggressive cell growth, invasion, and spread. Researchers are exploring ways to slow or stop this aggressiveness using a special variant of the SIRT6 protein, which is found in some exceptionally long-lived people (centenarians). This variant (N308K/A313S) improves DNA repair and fights cancer in other contexts; thus, this study examined whether delivering it to liver cancer cells via a safe viral vector could reduce harmful behaviors compared to the normal SIRT6 version. The findings show that the centenarian variant more strongly curbs cell multiplication and invasion while increasing cell stiffness (a sign linked to less aggressive movement), and that it alters genes related to tissue structure and matrix remodeling. These results suggest that the variant could help suppress liver cancer progression, offering new insights for the research community into potential gene-based therapies for this deadly disease and highlighting SIRT6’s role in cancer control.

............

6. Conclusions

Centenarian-associated SIRT6 N308K/A313S inhibited the aggressiveness and invasion of HCC cells. Clinically, these results position the N308K/A313S variant as a promising gene therapy target for HCC, especially given AAV2/8’s liver tropism and low immunogenicity [30]. Age-related incidence of HCC [25] and poor prognosis [1] underscore the value of longevity-inspired interventions. Our prior findings on the benefits of this variant in glucose sensitivity and fibrosis [26] extend to antitumor effects, potentially addressing metabolic drivers of HCC [14].

Future studies should investigate the variant’s impact on HCC stemness, chemoresistance, and patient-derived models, potentially integrating it with existing therapies. Targeting SIRT6 regulators, like microRNAs [12], or developing variant-specific activators could also enhance precision. Overall, this work advances understanding of SIRT6’s context-dependent roles in HCC and supports longevity-associated variants as novel therapeutic avenues to combat this malignancy.

Transcriptional Control of Hepatocellular Carcinoma Cells Aggressiveness by AAV2/8-Mediated Delivery of Human Centenarian-Associated SIRT6 N308K/A313S - PMC htTps://share.google/cd7jcMS6NHN3SDBV3

Healthy competition, and for Genflow, it's all about securing a lucrative commercial licensing/partnership deal with a Major Animal Healthcare Company, which would be truly transformational for all invested and given the stunning compelling efficacy data so far, such a deal could be very close. Gl ;-)

Both Loyal and Genflow Biosciences are pioneering the canine longevity market, but they approach the multibillion-dollar opportunity through distinct scientific methods and commercial strategies. Loyal is currently further ahead in terms of regulatory milestones and capital raised, while Genflow Biosciences is leveraging gene therapy with high potential for a first-in-class, transformative effect.

Market Potential Comparison

Market Size: The canine longevity market is viewed as a massive, untapped space, with over 90 million dogs in the US alone and rising spending on pet health.

Loyal (Drug Focus):

Status: Advanced with ~$250M raised in total, including a $100M Series C in Feb 2026.

Candidates: LOY-002 (daily pill for senior dogs) has two of three major technical sections accepted by the FDA. LOY-001 (for large dogs) has FDA agreement on "reasonable expectation of effectiveness".

Potential: Aims for conditional approval as early as 2026, making it a "first in the companion animal industry" product.

Genflow Biosciences (Gene Therapy Focus):

Status: Positive preliminary safety data from a small, controlled 28-dog trial (SIRT6) in elderly beagles.

Mechanism: Focuses on SIRT6 gene therapy to improve DNA repair and metabolic regulation.

Potential: Engaged with animal health companies for potential partnerships, licensing, or co-development.

Ai's take on proceedings....Gla ;-)

Genflow Biosciences PLC (LSE: GENF) has recently significantly expanded its Intellectual Property (IP) portfolio to secure its position in the longevity and gene therapy market.

As of April 2026, the company's IP strategy focuses on its proprietary SIRT6 gene therapy platform, specifically targeting age-related diseases.

Latest IP Developments

International Patent Publication: On 13 April 2026, Genflow announced the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, titled "Variants of Sirtuin 6 for the Treatment of Muscular Diseases".

Layered Protection: This filing expands protection for SIRT6 variants across multiple indications, including muscle atrophy, sarcopenia, and glaucoma.

European Milestones: The company previously reached the final phase of securing its cornerstone composition of matter patent in Europe, which establishes a broad defensive barrier against competitors.

Global Expansion: Genflow is actively reinforcing its IP portfolio in other major jurisdictions, including examinations in China.

Strategic Value of the IP Portfolio

Pharma Partnerships: Strong IP protection is a prerequisite for Genflow to attract large pharmaceutical partners for Phase 3 clinical trials, which the company is unlikely to fund independently.

Licensing Opportunities: The maturing IP position allows Genflow to pursue early-stage licensing deals to generate non-dilutive funding.

Core Technology: The IP strategy encompasses both composition of matter (the physical therapeutic) and methods of use, creating multiple entry barriers for competitors.

Key Therapeutic Programs Protected

GF-1002: A lead compound delivering a centenarian variant of the SIRT6 gene.

MASH: Programs exploring benefits for Metabolic Dysfunction-Associated Steatohepatitis.

Sarcopenia & Dog Studies: IP covers applications for both human and veterinary (dog) longevity.

Hopefully so....Gl :-)

The SIRT6 gene, sourced from human centenarians, plays a vital role in DNA repair, metabolic regulation, and resistance to age-related decline. By leveraging this unique gene variant, Genflow aims to introduce a new class of longevity-based treatments into the multi-billion-dollar global animal health market, targeting improved healthspan, vitality, and lifespan in companion and livestock animals.

WO2026062177 VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF MUSCULAR DISEASES https://share.google/ZvO93uvnhIT1lMZtD

Publication Number

WO/2026/062177

Publication Date

26.03.2026

International Application No.

PCT/EP2025/076784

International Filing Date

19.09.2025

.......................

WO2022241228 VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES https://share.google/bXdLantfFdjhSWxKw

Publication Number

WO/2022/241228

Publication Date

17.11.2022

International Application No.

PCT/US2022/029213

International Filing Date

13.05.2022

Yes, exactly what I said, the key patent Eric refers, in collaboration with Rochester, Einstein and Columbia, entered the National Phase last year, and according to Eric is "extremely close" to be approved and granted, which should add significant value to Genflow and all invested. Gl ;-)

End of March for Publication but filed 19/9/25

Publication Number

WO/2026/062177

Publication Date

26.03.2026

International Application No.

PCT/EP2025/076784

International Filing Date

19.09.2025

End of March for the latest one and 2022 for the treatment of age related diseases, which is the key patent Eric expects to be granted , "extremely close" . ...Gl :-)

The latest patent is a new international publication for Sirt6 variants for muscular disease ( sarcopenia etc ), and will have to go through the normal process and procedure before it's granted, whereas the "Key" patent Eric refers , is the one for Sirt6 variants for treating Age related disease developed in collaboration with the Albert Einstein College of Medicine, the University of Rochester, and Columbia University, whereby Genflow have exclusive worldwide rights, and is critically important to Genflow and potential partners going forward. News imminent i reckon. Gl ;-)

Yes indeed Steg, an incredibly exciting period ahead with the near term prospect of a lucrative commercial licensing deal with one or both of the Animal Healthcare companies, which would be a transformational and a total game changer and very likely propel Genflow from small cap towards mid cap in a blink, and given the stunning and compelling data so far, an early move could be highly likely, especially if the Animal Healthcare companies are in competition. In the meantime, Eric stated the granting of the key Sirt6 patent is "extremely close", ( presumably a necessity for Major Pharma to show their hand ) , and so news expected anytime now, which would be company defining going forward and add immediate significant value...In Eric we Trust!!! Gl :-)

One day Steg, I'm not on Telegram and I do like to support open public platforms such as LSE, and share and highlight information relevant to proceedings, regardless of those who wish I didn't ( over the years on various shares ). Gl :-)

Ps looks like we're poised and primed in anticipation of a potential re-rate on the next UPdate or two. "Excitement building!!! :-)

The granting of Genflow's Key Patent in geographical areas is "extremely close" , according to Eric's latest interview, which should add significant value, providing full ip protection and business development opportunities . Anytime now!!! Gla holders;-)

The advancement of its SIRT6 variants into the national phase at the EPO and Japanese Patent Office creates a defensible intellectual property portfolio. With a PATEX-2 grant application pending for U.S. and Chinese markets, the company is positioning itself to dominate a therapeutic class that could redefine age-related disease management.

Exciting times pickedpeck and very interesting and potentially highly significant Eric stated in his Oxford University Longevity presentation that it was "people from Merck " who had suggested Genflow should look into Sirt6's Gene Therapy potential for Dog healthspan and longevity, and so every chance Merck Animal Health could be one of the Animal Healthcare companies who have signed Confidential Disclosure Agreements. A deal with the multi-billion dollar Merck would be truly transformational and would potentially open the door for Merck Human Health for Genflow’s Sirt6 Gene Therapy Platform and so the upside could be off the scale. Genflow's Dog Therapy could be the perfect fit for Merck given they're focused on First in Class therapies along with strategic partnerships to achieve them. Hopefully not too long before we find out. Gl :-)

"Company executives said the preliminary results supported the potential of the SIRT6 gene therapy as a first-in-class approach to addressing age-related decline in companion animals and reinforced the programme’s relevance to prospective animal health partners.

Genflow said it was actively engaging with animal health companies regarding potential licensing, co-development and commercialisation opportunities."

Biopharma Research - MSD Animal Health https://share.google/jTFpZaKa84xwT4z5e

Biopharma Research

Healthy animals are the foundation of a healthy world. As threats to animal health evolve, so do our solutions. At MSD Animal health, we are committed to continuous innovation in biopharma research—not just to treat illness today, but to build a healthier, more resilient future for animals and the people who depend on them.

We are focused on advancing veterinary medicine in key therapeutic areas from combating parasites and infections to improving animal health and performance.

Development

We aim to be the first when it comes to discovering and developing first- and best-in-class veterinary medicines and vaccines. We have a proven track record in small molecules, vaccine technologies and biotechnologies, such as monoclonal antibodies.

Our robust portfolio of veterinary medicines and vaccines reflects our unwavering commitment to advancing veterinary medicine.

Innovation

We have some ambitious goals when it comes to advancing animal health and we know it will take strategic partnerships to achieve them. That’s why we invest in co-innovation partnerships with pharmaceutical, crop science companies and academic institutions, along with internal discovery efforts.

We also collaborate closely with our colleagues at MSD Human Health to share best practices and leverage the power of our combined research effort.

One year on....Gla ;-)

April 2025

CEO Dr Eric Leire talked with Proactive about the company’s new development program targeting eye health.

The initiative focuses on using a patented variant of the SIRT6 gene in combination with mRNA therapies. Leire explained that gene therapy is particularly well-suited for the eye due to its closed compartment, reducing the risks of off-target effects and immune responses.

The company is developing two parallel therapeutic applications: one for the posterior part of the eye to address glaucoma, and another for the anterior part, targeting corneal endothelial cell preservation in transplant procedures.

“We expect by a simple in vitro… to add our SIRT6 to these preservation media and help to increase the rate of positive transplantation of cornea,” said Leire, highlighting the opportunity to improve corneal transplant success rates without clinical trials.

Glaucoma therapy, on the other hand, involves a more complex delivery using mRNA injections, aiming to both reduce intraocular pressure and regenerate damaged ganglion cells. The company has already signed an MTA with an ophthalmology partner to initiate early development, starting with corneal preservation and expanding into glaucoma.

Genflow sees this as a fast-track opportunity to build an ophthalmology franchise with meaningful market potential and low incremental cost.

As usual, great work pickedpeck, exciting times for all invested. Eric stated in the Directors Talk interview, they're extremely close in having their key patent granted in geographical areas, which should add significant value with full ip protection in place, as well as highlighting ongoing discussions with Animal Healthcare companies for a lucrative licensing as they await the final data from the Dog Trial, which would transform Genflow's value. All bodes well. Gl :-)